Abstract:Age-related susceptibility to sepsis and endotoxemia is poorly defined, although hyperactivation of the immune system and the expansion of the visceral adipose as an immunological reservoir are underlying features. Macrophages from older organisms exhibit substantial changes, including chronic NLRP3 inflammasome activation, genomic remodeling and a dysfunctional, amplified inflammatory response upon new exposure to pathogen. However, the mechanisms by which old macrophages maintain their inflammatory phenotype during endotoxemia remains elusive. We previously identified Gdf3, a TGFβ superfamily cytokine, as a top-regulated gene by age and the NLRP3 inflammasome in adipose tissue macrophages (ATMs). Here, we demonstrate that endotoxemia increases inflammatory (CD11c+) ATMs in a Gdf3-dependent manner in old mice. Lifelong systemic or myeloid-specific deletion of Gdf3 leads to reduced endotoxemia-induced inflammation, with decreased CD11c+ ATMs and inflammatory cytokines, and protection from hypothermia. Moreover, acute blockade of Gdf3 using JQ1, a BRD4 inhibitor, phenocopies old mice with lifelong Gdf3-deficiency. We show that GDF3 promotes the inflammatory phenotype in ATMs by phosphorylating SMAD2/3. Mechanistically, the differential chromatin landscape of ATMs from old mice with or without myeloid-driven Gdf3 indicates that GDF3-SMAD2/3 signaling axis shifts the chromatin accessibility of ATMs towards an inflammatory state during aging. Furthermore, pharmaceutical inhibition of SMAD3 with a specific inhibitor of SMAD3 (SIS3) mimics Gdf3 deletion. SIS3 reduces endotoxemia-mediated inflammation with fewer CD11c+ ATMs and less severe hypothermia in old, but not young mice, as well as reduced mortality. In human adipose tissue, age positively correlates with GDF3 level, while inflammation correlates with pSMAD2/3 level. Overall, these results highlight the importance of GDF3-SMAD2/3 axis in driving inflammation in older organisms and identify this signaling axis as a promising therapeutic target for mitigating endotoxemia-related inflammation in the aged.

GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process

Growth Differentiation Factor-15 in Immunity and Aging

GDF-15 As a Biomarker of Aging

Growth differentiation factor 15 protects against the aging‐mediated systemic inflammatory response in humans and mice

GDF3 promotes adipose tissue macrophage-mediated inflammation via altered chromatin accessibility during aging

GDF15 as a biomarker of ageing

Mutual Regulation Between GDF11 and TET2 Prevents Senescence of Mesenchymal Stem Cells

Macrophages as a Source and Target of GDF-15

Depletion of growth differentiation factor 15 (GDF15) leads to mitochondrial dysfunction and premature senescence in human dermal fibroblasts

Association of GDF15 With Inflammation and Physical Function During Aging and Recovery After Acute Hospitalization: A Longitudinal Study of Older Patients and Age-Matched Controls

cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging

Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease

GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance

GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing

The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis

Associations of Serum GDF-15 Levels with Physical Performance, Mobility Disability, Cognition, Cardiovascular Disease, and Mortality in Older Adults

In vivo GDF3 administration abrogates aging related muscle regeneration delay following acute sterile injury

Macrophage Inhibitory Cytokine-1/Growth Differentiation Factor 15 As a Marker of Cognitive Ageing and Dementia

Circulating GDF-15: a biomarker for metabolic dysregulation and aging in people living with HIV

IgG is an aging factor that drives adipose tissue fibrosis and metabolic decline

TGF-β Signaling in Cellular Senescence and Aging-Related Pathology